Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) overview
Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of adrenoleukodystrophy (adrenomyeloneuropathy/Schilder-Addison complex). Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in the gene that tells the body to create lipoproteins. Symptoms include curvature of the spine, muscle weakness, and decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.
For a complete picture of PTSR and LoA scores for drugs in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
